The Bio Report
Levine Media Group
Publishing Details
About This Podcast
Explore Statistics
Recent Episodes
Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug
Epigenetics, the layer of chemical switches that controls how genes are turned on and off, can act like cancer’s operating system when a single epigenetic enzyme becomes essential for a tumor to…
Rewriting the Rules of Antibody Drug Design
Most marketed antibodies work as antagonists, simply shutting off a receptor, even though many immune, metabolic, and cancer pathways require more nuanced control. Metaphore Biotechnologies'…
Mapping Cellular Stress Biology to Tackle Undruggable Targets
Cells continuously sense their environment and in response to stressors, adapt, recover, or die. Soley Therapeutics uses its AI platform to capture thousands of intracellular features and map how…
Turning Abandoned Drugs into Breakthroughs
Promising drugs can become abandoned or underused because of tolerability issues, poor drug‑like properties, or other fixable limitations, even when there is already compelling human evidence that…
Targeting Cancer Survival Genes in Solid Tumors
Most cancer therapies hit one or a few pathways that tumors can escape by mutating, activating alternative survival routes, or pumping drugs out, leading to relapse and poor survival in indications…
Addressing Treatment Gaps in Gout
Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering for millions of people who are often blamed for their…
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
Small molecule drugs and monoclonal antibodies often fall short at addressing severe inflammatory and immune‑mediated diseases. Mesoblast has spent more than 15 years industrializing mesenchymal…
Slowing Disability in MS
Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives long-term disability,…
Tuning, Rather than Blocking, Immunity in IBD
The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risks, and drive high treatment cycling. Abivax is betting…
Intercepting Cancer When DNA Surveillance Fails
Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few options beyond constant screening and, in some cases, preventive…
Targeting Psychosis in Alzheimer’s Disease
Alzheimer’s disease drug development has long focused on slowing memory loss, but for many families, the tipping point that makes home care impossible is not cognition—it is psychosis. Hallucinations…
A Class Action Suits Moves RICO from Mobsters to Medicine
RICO, the Racketeer Influenced and Corrupt Organizations Act, was originally designed to prosecute organized crime. Today, it sits at the center of a landmark class action against two of the world’s…
Outsmarting Resistance with Rhythm
Pancreatic cancer remains one of oncology’s deadliest diagnoses, with standard treatments often offering only transient tumor shrinkage at the cost of grueling side effects and rapid resistance.…
Editing Away Autoimmunity at the HLA Source
Human leukocyte antigen, or HLA, genes, help the immune system tell the difference between the body’s own tissues and outside threats. In some people, certain versions of HLA genes mistakenly flag…
Why Asia is the Emerging Epicenter for Global Biopharmaceutical Progress
Asia is quickly becoming a powerhouse for biopharma innovation, changing ideas about where breakthrough science and fast, cost-efficient drug development happen. A new McKinsey & Company report…
Reprogramming Cancer from Within
Leukemia once threatened Aaron Viny’s life, but now it defines his mission. Diagnosed with acute lymphoblastic leukemia as a college student, he survived chemotherapy, central nervous system relapse,…
A Strategic Turn from Obesity to Cancer
When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead a strategic shift from an increasingly crowded…
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer Non–muscle invasive bladder cancer is a common, slow-progressing form of bladder cancer that makes up a majority of the roughly half…
Reprogramming T Cells to Cross the Brain’s Border
One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that harnesses a patient’s own T…
A Billion-Dollar Bet on AI-First Drug Development
Despite the emergence of new modalities and drug development technologies, the cost and time to produce new therapies has changed little, and failure rates remain high. Xaira aims to change that with…
Frequently Asked Questions
The Bio Report has published 619 episodes since August 2014, covering topics in Business, Health & Fitness.
The Bio Report is currently highly active with new episodes weekly. Average episode length is 25m.
Similar Podcasts
19 Keys Presents High Level Conversations
EYL Network
484 episodes
Huberman Lab
Scicomm Media
414 episodes
Yoga Therapy Hour with Amy Wheeler
Amy Wheeler
247 episodes
Random Musings From The Clinical Trials Guru
Dan Sfera
299 episodes
Innovate and Elevate
Sharon Kedar, MBA, CFA
23 episodes
THE EMBC NETWORK Featuring: ihealthradio and Worldwide Podcasts
Hurricane H
837 episodes